AFQ056 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Fragile X Syndrome

Conditions

Fragile X Syndrome

Trial Timeline

Aug 17, 2017 → May 17, 2022

NCT ID

NCT02920892

About AFQ056 + Placebo

AFQ056 + Placebo is a phase 2 stage product being developed by Novartis for Fragile X Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02920892. Target conditions include Fragile X Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04771143	Phase 1	Withdrawn	Jul 21, 2021	Jan 3, 2022	Cocaine Use Disorder
NCT03242928	Phase 2	Completed	Dec 4, 2017	Dec 16, 2019	Cocaine-related Disorder
NCT02920892	Phase 2	Completed	Aug 17, 2017	May 17, 2022	Fragile X Syndrome
NCT01813019	Phase 2	Terminated	Nov 1, 2013	Nov 1, 2014	Patient Diagnosed With OCD and Resistant to SSRI Treatment
NCT01491529	Phase 2	Completed	Apr 1, 2012	Apr 1, 2013	Dyskinesias
NCT01385592	Phase 2	Completed	Nov 1, 2011	Sep 1, 2012	Dyskinesias
NCT01357239	Phase 2	Completed	May 1, 2011	Jan 1, 2014	Fragile X Syndrome
NCT01253629	Phase 2	Completed	Nov 1, 2010	Aug 1, 2013	Fragile X Syndrome
NCT01019473	Phase 2	Terminated	Nov 1, 2009	—	Huntington's Disease
NCT00888004	Phase 2	Completed	Mar 1, 2009	—	Parkinson's Disease
NCT00582673	Phase 2	Completed	Oct 1, 2007	—	Parkinson's Disease

Competing Products

14 competing products in Fragile X Syndrome

See all competitors

Product	Company	Stage	Hype Score
CTH120	Connecta Therapeutics	Phase 1	25
AFQ056	Novartis	Phase 1	33
AFQ056	Novartis	Phase 2/3	65
AFQ056 + Placebo	Novartis	Phase 2	52
AFQ056 + Placebo	Novartis	Phase 2	52
AFQ056	Novartis	Phase 2	52
AF056 + Placebo	Novartis	Phase 2	52
Placebo + RO4917523 + RO4917523	Roche	Phase 2	52
Placebo (for RO4917523 ascending doses) + Placebo (for RO4917523 fixed dose) + RO4917523 + RO4917523	Roche	Phase 2	52
Placebo + RO4917523 0.5 mg + RO4917523 1.5 mg	Roche	Phase 2	52
CBD Oral Solution + Placebo	Jazz Pharmaceuticals	Phase 2	49
CBD Oral Solution (eCBD system Target) + Placebo	Jazz Pharmaceuticals	Phase 2	49
Low dose of MRM-3379 + Middle Dose of MRM-3379 + High dose of MRM-3379 + Placebo + Low dose of MRM-3379 Open-Label	Mirum Pharmaceuticals	Phase 2	49
NNZ-2566 + Placebo	Neuren Pharmaceuticals	Phase 2	47

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved